EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Optimizing the Safe Washout Period for Liver Transplantation Following Immune Checkpoint Inhibitors with Atezolizumab, Nivolumab, or Pembrolizumab

Fang-Cheng Kuo, Cheng-Yen Chen, Niang-Cheng Lin, Chinsu Liu, Cheng-Yuan Hsia, Che-Chuan Loong

Transplantation Proceedings · 2023

DOI: 10.1016/j.transproceed.2023.03.064 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Transplantation Proceedings, 2023. Verfasst von Fang-Cheng Kuo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Transplantation Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan; School of Medicine, National Yang Ming …. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Hepatocellular, Liver Transplantation, Liver Neoplasms. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Using immune checkpoint inhibitors (ICIs) as a downstaging therapy for liver transplantation (LT) has improved outcomes for patients with advanced hepatocellular carcinoma (HCC). However, this therapy carries a risk of post-transplant graft rejection. The washout (WO) period between the last ICI dose and LT seems critical in preventing postoperative rejection. This study aimed to optimize the WO period by balancing tumor burden suppression and rejection prevention using ICIs before LT. METHODS: We reviewed published case reports or series from March 2020 to December 2022 regarding LT for HCC after downstaging or bridge therapy with ICIs and included 4 of our cases. Most patients received atezolizumab, nivolumab, or pembrolizumab; these ICIs shared a half-life of around 28 days. Therefore, we excluded cases without definite WO period data and those using non-atezolizumab/nivolumab/pembrolizumab ICIs and ultimately enrolled 22 patients for analysis. We compared their clinical outcomes and estimated the rejection-free survival for every 0.5 half-life interval. RESULTS: Most study subjects received nivolumab (n = 25). Six patients had severe rejections (nivolumab group, n = 5) and needed rescue management. Of the 6 cases, 1 patient died after rejection, and 2 underwent re-transplantation. The median WO period in these 6 patients was 22 days (IQR: 9-35 days). In addition, we found that a 1.5 half-life (42 days) was the shortest safe WO period associated with significant rejection-free survival (P = .005). CONCLUSIONS: Our results showed that 42 days was the safest WO period before LT for HCC after ICI with atezolizumab, nivolumab, or pembrolizumab.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsCarcinoma, HepatocellularLiver TransplantationLiver NeoplasmsHumansNivolumabImmune Checkpoint InhibitorsAntibodies, Monoclonal, Humanized

Substanzen

NivolumabImmune Checkpoint InhibitorspembrolizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Division of Transplantation Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan; School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
  • Division of Transplantation Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan; Institute of Public Health, National Yang Ming Chiao Tung University, Taipei, Taiwan; School of Medicine, Nat…
  • Division of General Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan; School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.

Zitieren

APA

Kuo, F. C., Chen, C. Y., Lin, N. C., Liu, C., Hsia, C. Y., & Loong, C. C. (2023). Optimizing the Safe Washout Period for Liver Transplantation Following Immune Checkpoint Inhibitors with Atezolizumab, Nivolumab, or Pembrolizumab. Transplantation Proceedings. https://doi.org/10.1016/j.transproceed.2023.03.064

Vancouver

Kuo FC, Chen CY, Lin NC, Liu C, Hsia CY, Loong CC. Optimizing the Safe Washout Period for Liver Transplantation Following Immune Checkpoint Inhibitors with Atezolizumab, Nivolumab, or Pembrolizumab. Transplantation Proceedings. 2023. doi:10.1016/j.transproceed.2023.03.064

BibTeX
@article{Kuo2023,
  author = {Kuo, Fang-Cheng and Chen, Cheng-Yen and Lin, Niang-Cheng and Liu, Chinsu and Hsia, Cheng-Yuan and Loong, Che-Chuan},
  title = {Optimizing the Safe Washout Period for Liver Transplantation Following Immune Checkpoint Inhibitors with Atezolizumab, Nivolumab, or Pembrolizumab},
  journal = {Transplantation Proceedings},
  year = {2023},
  doi = {10.1016/j.transproceed.2023.03.064}
}
Kostenlos starten →